Mortality, survival rate, presenting symptoms, delay to diagnosis, metastatic disease at diagnosis, and therapy abandonment are clinical indicators that should be monitored at the national and subnational levels to assess for Rb management advancements. The gene discussed is RB1; the disease is metastatic neoplasm.